Anti-tumor efficacy of gavo-cel
tumor
TUMOR
Of the 32 patients who received gavo-cel, 30 were evaluable for tumor response assessment. Two patients who experienced grade 5 AEs before their post-infusion computed tomography (CT) scan were not evaluable for response. After gavo-cel infusion, all but two patients (93%) experienced a decrease in the sum of target lesion diameters, ranging in magnitude from 4% to 80% (Fig. 